Objective: To describe mechanical ventilation settings in adult patients treated for an acute respiratory distress syndrome with extracorporeal membrane oxygenation and assess the potential impact of mechanical ventilation settings on ICU mortality. Design: Retrospective observational study. Setting: Three international high-volume extracorporeal membrane oxygenation centers. Patients: A total of 168 patients treated with extracorporeal membrane oxygenation for severe acute respiratory distress syndrome from January 2007 to January 2013. Interventions: We analyzed the association between mechanical ventilation settings (i.e. plateau pressure, tidal volume, and positive end-expiratory pressure) on ICU mortality using multivariable logistic regression model and Cox-proportional hazards model. Measurement and Main Results: We obtained detailed demographic, clinical, daily mechanical ventilation settings and ICU outcome data. One hundred sixty-eight patients (41 ± 14 years old; Pao 2 /Fio 2 67 ± 19 mm Hg) fulfilled our inclusion criteria. Median duration of extracorporeal membrane oxygenation and ICU stay were 10 days (6-18 d) and 28 days (16-42 d), respectively. Lower positive end-expiratory pressure levels and significantly lower plateau pressures during extracorporeal membrane oxygenation were used in the French center than in both Australian centers (23.9 ± 1.4 vs 27.6 ± 3.7 and 27.8 ± 3.6; p < 0.0001). Overall ICU mortality was 29%. Lower positive end-expiratory pressure levels (until day 7) and lower delivered tidal volume after 3 days on extracorporeal membrane oxygenation were associated with significantly higher mortality (p < 0.05). In multivariate analysis, higher positive end-expiratory pressure levels during the first 3 days of extracorporeal membrane oxygenation support were associated with lower mortality (odds ratio, 0.75; 95% CI, 0.64-0.88; p = 0.0006). Other independent predictors of ICU mortality included
; Claire Stewart, MBBS (Hons), BSc (Adv) 3, 4 ; Michael Bailey, PhD, MSc (Statistics), BSc (Hons) 1, 5 ; Ania Nieszkowska, MD 2 ; Joshua Kelly, BBiomedSc/BE 1 ; Lorna Murphy, MBBS 3, 4 ; David Pilcher, MRCP, FRACP, FCICM; 1, 5 D. James Cooper, BMBS, MD 1, 5 ; Carlos Scheinkestel, MBBS 5 ; Vincent Pellegrino, MBBS 1, 5 ; Paul Forrest, MBChB, FANZCA 3, 4 ; Alain Combes, MD, PhD 2 ; Carol Hodgson, PhD, FACP 1, 5 time between ICU admission and extracorporeal membrane oxygenation initiation, plateau pressure greater than 30 cm H 2 O before extracorporeal membrane oxygenation initiation, and lactate level on day 3 of extracorporeal membrane oxygenation support. Conclusions: Protective mechanical ventilation strategies were routinely used in high-volume extracorporeal membrane oxygenation centers. However, higher positive end-expiratory pressure levels during the first 3 days on extracorporeal membrane oxygenation support were independently associated with improved survival. Further prospective trials on the optimal mechanical ventilation strategy during extracorporeal membrane oxygenation support are warranted. (Crit Care Med 2015; 43:654-664) Key Words: acute respiratory distress syndrome; adult; extracorporeal membrane oxygenation; mechanical ventilation; outcome M echanical ventilation (MV) remains the cornerstone of management in patients with acute respiratory distress syndrome (ARDS) care, and numerous large randomized controlled trials have investigated different ventilation strategies (1) (2) (3) (4) . Despite recent trials on rescue therapies (5) (6) (7) (8) , the management of severe ARDS remains challenging. Extracorporeal membrane oxygenation (ECMO) was initially derived from conventional cardiopulmonary bypass circuits used in operating theatres, and previous efforts to expand its application to ARDS were marred by high complication rates (9, 10) . Technological advances in centrifugal pumps, polymethylpentene (diffusion) membrane oxygenators, and heparin-bonded circuits have largely overcome these early technical problems (11) . In addition, the promising outcomes during the 2009 influenza A (H 1 N 1 ) pandemic (12) and the conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure trial (13) have renewed interest in venovenous ECMO (VV-ECMO) as a salvage therapy for patients with severe ARDS. By replacing the usual functions of ventilation, ECMO facilitates ultraprotective ventilation strategies, potentially minimizing ventilation-induced lung injury (14) . Although there is high level evidence that low-tidal volume (VT) ventilation improves survival (1, 15) in ARDS, ventilation strategies during ECMO have received little attention (16) . Ultraprotective ventilation strategies are supported in a few experimental studies (17, 18) , but there are no evidence into a clinical benefit of ventilation strategies during ECMO support (19) and therefore little consensus regarding optimal ventilator management. Practices are guided by clinician preference, experience of high-volume centers and local resource availability (16) . The purpose of this study was therefore to describe MV settings in adult patients treated for ARDS with ECMO in three international high-volume ECMO centers and assess the potential impact of MV settings on ICU mortality
PATIENTS AND METHODS

Setting
This study was conducted in three university hospital centers with medical-surgical ICUs: a 45-bed ICU in Melbourne, Australia (The Alfred Hospital), a 49-bed ICU in Sydney, Australia (Royal Prince Alfred Hospital), and a 26-bed ICU in Paris, France (La Pitié-Salpêtrière Hospital). Each center supports more than 30 ECMO cases annually (20, 21) . In addition, each hospital provides a referral and retrieval service for patients requiring ECMO support in regional centers. Ethics approval was obtained in each participating institution, and the need for informed consent was waived.
Patients
We retrospectively analyzed the hospital records of 60 consecutive patients per center (n = 180), who received ECMO for refractory ARDS from January 2007 to January 2013 (Melbourne and Sydney) or from January 2011 to January 2013 (Paris). Study patients were included if they received ECMO for more than 24 hours, and data on MV settings were available. Two patients were excluded being enrolled in the Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome trial (22) . One hundred sixty-eight patients were eligible for enrolment in the analysis (Fig. 1) .
Hospital Characteristics and ECMO Management
Detailed center-specific characteristics and criteria for assessing ECMO for ARDS are provided in eTable 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B140). Percutaneous VV-ECMO was used in all cases. In the Australian centers, the commonest configuration was femoro-femoral (with additional jugular access if required), whereas the French center mostly used a femoro-jugular configuration. Although MV on ECMO was not standardized between study centers, each center used lung protective strategies to minimize plateau pressures.
Data Collection
Demographic data, Acute Physiology and Chronic Health Evaluation (APACHE II) (23) and Sequential Organ Failure Assessment (SOFA) (24) were collected at the time of ECMO initiation. Date of hospital and ICU admission, date of initiation of MV and ECMO, primary indication for ECMO, preexisting immunodeficiency according to APACHE II criteria (23) , and surgical intervention within 7 days before ECMO initiation were also recorded. Adjunctive rescue therapies prior to ECMO support were recorded (nitric oxide, neuromuscular blocker agents, prone positioning, or high-frequency oscillatory ventilation), along with ECMO cannulation configuration and retrieval cases. Once established on ECMO, the following patient variables were collected once daily at 10 am (or nearest available result), from 24 hours before ECMO support until support withdrawal, death, or day 28 (whichever occurred first): 1) level of sedation using the Richmond Agitation-Sedation Scale (RASS) (25) as bleeding, which lead to a hemostatic treatment (pleural drainage, surgical procedure, arterial embolization, and gastrointestinal endoscopy), a transfusion greater than or equal to five blood units of packed RBCs during 24 hours, in cases of intracerebral hemorrhage or death. Maximal ionotrope dose per day was calculated as the addition of the daily maximal epinephrine and maximal norepinephrine doses, respectively. Status at ICU discharge and duration of MV and ECMO support were recorded.
Outcome Measures
The primary endpoint was to examine the management of MV during ECMO, including mode, VT, plateau pressure, and PEEP. These data were collated for six intervals: "pre-ECMO," "day 1-3," "day 4-7," "day 8-14," "day 15-21," and "day 22-28." Secondary endpoints were to examine whether any MV variables either before or during early ECMO support were associated with ICU mortality.
Statistical Analyses
Data were initially assessed for normality. Normally distributed continuous variables were compared using Student t tests or analysis of variance and presented as mean±sd, whereas nonnormally distributed variables were compared using Wilcoxon rank sum tests or Kruskal-Wallis tests and presented as median (interquartile range). Categorical variables were compared using chi-square test for equal proportion or Fisher exact tests and have been reported as numbers (percentages). Changes over time were analyzed using repeated-measures analysis of variance fitting main effects for group, time, and an interaction between group and time with results presented as least square means (95% CI).
Multivariate logistic regression was used to identify early independent risk factors for ICU mortality in patients receiving ECMO, with results presented as odds ratios (95% CI). Multivariate models were constructed using both stepwise selection and backward elimination techniques before undergoing a final assessment for clinical and biological plausibility. A cox proportional hazard modeling was also applied to data analysis. Multivariate modeling was done including patient information until day 3. Thus, three patients with ICU length of stay (LOS) less than 3 days (i.e. 48 hr) were not included in the model. With the exception of the "country "(i.e. Australia or France)" (automatically forced into the model), all other variables before day 3 with a univariate value of p less than 0.10 were considered for model inclusion. Possible interactions between independent risk factors (including "country") were tested by including proper crossproduct terms in the regression models, and likelihood ratio tests comparing models with and without the interaction term were used to estimate the significance of the interaction.
Analysis were performed using SAS version 9.3 (SAS Institute, Cary, NC), and a two-sided value of p equal to 0.05 was considered to be statistically significant.
RESULTS
Characteristics of Included Patients
A total of 168 severe patients with ARDS (age, 41 ± 14 years; 62% men) were enrolled in the study, of whom 98% received VV-ECMO (Fig. 1) . Details of patient characteristics are provided in Table 1 . Bacterial pneumonia and influenza infection were the main risk factors for ARDS requiring ECMO support. Median time to initiation of ECMO was 2 days (1-6 d) after commencement of MV. Of note, French patients were older, had higher severity scores at ICU admission and ECMO cannulation, and had less influenza as the reason for ARDS (Table 1 ). They also had a longer period of MV prior to initiation of ECMO, while they received more rescue therapies (p < 0.05). MV data in the French patients revealed higher median driving pressures and lower median compliance before ECMO initiation in more severe patients with mainly bacterial pneumonia (i.e. less patients with influenza). Clinician-determined pre-ECMO VT and subsequent pre-ECMO plateau pressures were similar within the three ICUs; however, PEEP before ECMO was lower in Paris (p < 0.0001; Table 1 ).
MV Management During ECMO
This study reported daily MV management during a total of 2514 ECMO days. Fifty-five percent of patients received pressure targeted modes (i.e. airway press release ventilation/bilevel positive airway pressure/synchronized intermittent mechanical ventilation/pressure control and pressure-control ventilation [PCV]) before ECMO initiation, whereas it increased up to 90% and 85% at day 1 and day 7 during ECMO (eFig. 1, Supplemental Digital Content 1, http://links.lww.com/CCM/B140).
ECMO initiation facilitated significant reduction in the proportion of patients with a plateau pressure greater than 30 cm H 2 O, falling from 58% to 13% by ECMO day 3 ( Fig. 2A) . Once established on ECMO support, a median plateau pressure of 26 cm H 2 O was maintained throughout the ICU course in both survivors and nonsurvivors (Fig. 2B) . Similarly, VT was reduced from 6.3 ± 1.5 to 3.9 ± 1.6 after ECMO initiation (Fig. 3) . After 4 days on ECMO, ICU survivors exhibited significantly higher VT than nonsurvivors, despite both receiving targets of VT less than 6 mL/kg with plateau pressure less than 28 cm H 2 O. VT in 29% patients was less than 2 and greater than 6 mL/kg in 15% (Fig. 3A) . Consistent with previously described protective strategies, almost 80% of patients were ventilated with a PEEP greater than or equal to 10 cm H 2 O; however, patients who died in ICU received significant lower PEEP during the first week of ECMO support. Of note, a lower PEEP from day 1 to day 7 was associated with a higher prevalence of pneumothorax pre-ECMO or during the first ECMO week (p = 0.047).
MV management during the first 3 days on ECMO varied between centers. Lower PEEP (10 ± 2 vs 14 ± 3 and 12 ± 3; p < 0.0001) and lower plateau pressures (23.9 ± 1.4 vs 27.6 ± 3.7 and 27.8 ± 3.6; p < 0.0001) were used in the French center than in both Australian centers. In addition, patients in Australian sites received more sedation, as suggested by a significantly more negative RASS during the first days of the ECMO course (Table 1) .
Outcomes
Nearly half of the patients received renal replacement therapy during their ICU stay and 22% underwent tracheotomy on ECMO. Duration of ECMO and MV was 10 days (6-18 d) and 23 days (13-37 d), respectively, with no significant difference between centers. However, we observed a longer ICU LOS in Paris, whereas there was no difference between the centers for ECMO-free days at day 28 and MV-free days at day 60 (Table 1) . Table 3) . Consistently, a higher PEEP for MV while on ECMO was independently associated with a longer "time to death in ICU" using Cox proportional hazards modeling (Table 3 ). In addition, higher PEEP was still independently associated with reduced death in ICU when the multivariate logistic regression was performed on the Australian population only (eTable 3, Supplemental Digital Content 1, http:// links.lww.com/CCM/B140).
No significant interactions between "country," "interval between ICU admission and ECMO initiation," "plateau pressure before ECMO less than 30 cm H 2 O," "PEEP from day 1 to 3 on ECMO," and "lactate at day 3" were found.
DISCUSSION
Although previous studies have examined outcomes of patients with ARDS receiving ECMO support (12, 26, 27) , there are little data on MV during ECMO support (28) . Although ECMO support facilitates the provision of "ultraprotective" MV, the ideal MV strategy on ECMO is unknown.
We found that in three experienced ECMO centers, MV settings during ECMO varied significantly. We also found that higher plateau pressures prior to ECMO and lower PEEP levels during the first 3 days on ECMO support were independently associated with increased ICU mortality. 
MV Settings and Outcomes
Assist-volume control ventilation is the most common MV mode worldwide for patients with ARDS (29) . Less than 40% of patients with conventionally managed ARDS receive PCV in large observational studies (29) . By contrast, we found that PCV was used in nearly all cases during the first week of ECMO support. Limiting pressure during MV provided lung protection by minimizing barotrauma in both assistvolume control ventilation and PCV, whereas recovery of lung compliance is easily monitored in PCV by increasing VT for the set pressure (16).
Our finding that elevated MV plateau prior to ECMO was associated with increased mortality is consistent with a reported relationship between decreased lung compliance and mortality (27) . Higher pre-ECMO plateau pressure was associated with shorter time to death. We observed a major reduction in plateau pressure (< 30 cm H 2 O) after ECMO initiation in all centers (Fig. 2B) .
Limiting MV plateau pressure after ECMO was established by decreasing VT on day 1 to 3 to less than 4 mL/kg ideal body weight (Fig. 3B) , which is consistent with "ultraprotective ventilation" (13, 30) . Although animal and human experimental studies report less pulmonary edema and lung injury with VT below 4 mL/kg (17, 31) , a recent multicenter randomized controlled trial failed to demonstrate 28 and 60 days ventilator-free days benefit from ultra versus conventionally protective MV (19) . However, it is worth noting that a post hoc analysis demonstrated that surviving patients with greater hypoxemia, who would likely be treated with ECMO, were treated with Co 2 removal devices and had a significantly shorter period of ventilation compared to control (19) .
The importance of PEEP in ARDS is well described, but its use remains controversial (3, 4, 32) . The Extracorporeal Life Support Organization recommends a PEEP of 10 cm H 2 O during ECMO support (28) . In our study, the median PEEP during the first 3 days of ECMO support was 12 ± 3 cm H 2 O; however, we noted significant differences in PEEP values between countries. In addition, it is worth noting that a higher prevalence of pneumothorax may have led to lower PEEP levels in our population. Our observation of an independent association between early high PEEP level and reduced mortality in ECMO patients, regardless of management's differences within countries, merits further investigation. Potential benefits of PEEP include reduced atelectasis (33, 34) and improved ventilation/perfusion matching, especially when VT is less than 4 mL/kg (33) . In the cohort of patient with a very low VT (< 2 mL/kg; Fig. 3A ), higher PEEP might also maintain convective ventilation to prevent atelectasis induced by alveolar nitrogen accumulation during apneic oxygenation on ECMO support (34) although it may also cause alveolar overdistension (35) and hemodynamic impairment. It might be worth considering the potential benefit of recruitment maneuvers in those patients (36, 37) , especially at the early stage of the ECMO course. However, the combination of these two rescue therapies has not been investigated, and physiological studies are needed to support this hypothesis. Finally, the association between higher VT after day 4 (but maintained < 6 mL/kg with a constant plateau pressure) and ICU survival may support the great impact of the respiratory compliance on outcome in these patients.
Other Prognostic Factors
Several studies (27, (38) (39) (40) have demonstrated an adverse relationship between duration of MV prior to ECMO initiation and mortality, especially after 7 days (27, 41) . In our study, almost all patients received ECMO within 7 days of MV although we were still able to identify duration between ICU admission and ECMO as a risk factor for mortality. Further trials are therefore needed on the use and optimal timing of ECMO support in ARDS. Moreover, it raises compelling questions about the value and timing of others rescues therapies before cannulation. Ongoing trials may answer this concern soon (22) . It is worth noting that APACHE II was not retained in our multivariate models. Considering that this severity score is calculated at ICU admission, its performance may not likely be as good as the SOFA score, which is performed at ECMO initiation. Finally, in the absence of significant interaction between independent risk factors of the model, MV differences between France and Australia cannot explain the shorter time to ICU death in Australia. Some unknown confounding factors might have contributed to this result.
Strengths and Limitations
Our study is the first detailed examination of MV settings and outcome in a large cohort of patients with ARDS from high-volume ECMO centers. Our study has several limitations, including its retrospective design. In addition, we cannot exclude that the result might have been biased by residual confounding not accounted for in this study. For logistic reasons, MV settings were collected as point data once a day. We are aware that MV is a continuous, dynamic function of our daily practice, and settings may have changed rapidly with a 24-hour period, especially during the start of the ECMO course. Data from only the first 3 days of ECMO support were included for analysis of mortality, because beyond this time, the size of our cohort was reduced to a number that prevented accurate multivariate analysis. Whether specific MV strategies after day 3 on ECMO would change patient outcomes is yet to be determined, and larger prospective study may overcome this difficulty.
CONCLUSIONS
We found that early higher PEEP with MV during ECMO support was associated with decreased mortality. Further large, prospective trials on MV management during ECMO are warranted. 
